Oppenheimer Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target reduced by Oppenheimer from $1,150.00 to $1,000.00 in a research report report published on Wednesday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on the company. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, TD Cowen boosted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,107.25.

Regeneron Pharmaceuticals Trading Up 0.5 %

Shares of REGN stock opened at $828.42 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a fifty day simple moving average of $1,021.70 and a two-hundred day simple moving average of $1,036.38. The firm has a market capitalization of $91.04 billion, a PE ratio of 20.50, a PEG ratio of 3.12 and a beta of 0.15. Regeneron Pharmaceuticals has a 52-week low of $783.57 and a 52-week high of $1,211.20.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.48% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Cornerstone Advisors LLC lifted its position in Regeneron Pharmaceuticals by 13.2% during the third quarter. Cornerstone Advisors LLC now owns 6,000 shares of the biopharmaceutical company’s stock valued at $6,307,000 after acquiring an additional 700 shares during the last quarter. Moran Wealth Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 13.1% in the 3rd quarter. Moran Wealth Management LLC now owns 22,216 shares of the biopharmaceutical company’s stock worth $23,354,000 after purchasing an additional 2,572 shares in the last quarter. Retireful LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $751,000. Portfolio Design Labs LLC increased its position in Regeneron Pharmaceuticals by 9.4% during the 3rd quarter. Portfolio Design Labs LLC now owns 302 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 26 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Regeneron Pharmaceuticals by 115.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 20,511 shares of the biopharmaceutical company’s stock valued at $21,562,000 after buying an additional 11,008 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.